Miragen Therapeutics Inc Stock Cinnober Boat
Stocks
US60463E1038
Biotechnology & Medical Research
| Market Cap | 2.58B 0 2.22B 2.09B 1.9B 3.56B 245B 3.57B 24.73B 9.56B 125B 9.67B 9.46B 395B | P/E 2026 * |
-5.73x | P/E 2027 * | -8.81x |
|---|---|---|---|---|---|
| Enterprise Value | 1.79B 0 1.54B 1.45B 1.32B 2.47B 170B 2.48B 17.17B 6.64B 86.68B 6.71B 6.57B 275B | EV / Sales 2026 * |
64x | EV / Sales 2027 * | 8.96x |
| Free-Float |
99.32% | Yield 2026 * |
-
| Yield 2027 * | - |
Last Transcript : Miragen Therapeutics Inc
| Manager | Title | Age | Since |
|---|---|---|---|
Stephen Mahoney
CEO | Chief Executive Officer | 55 | 2023-10-29 |
Seth Harmon
DFI | Director of Finance/CFO | 46 | 2023-09-11 |
Kirk Bertelsen
CTO | Chief Tech/Sci/R&D Officer | - | 2023-12-31 |
| Director | Title | Age | Since |
|---|---|---|---|
Arlene Morris
BRD | Director/Board Member | 74 | 2018-01-02 |
Tomas Kiselak
CHM | Chairman | 39 | 2021-05-31 |
Jennifer Moses
BRD | Director/Board Member | 51 | 2021-07-13 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -.--% | -.--% | - | - | 2.62B | |
| -3.24% | -7.78% | -5.35% | +11.20% | 48.01B | |
| +0.17% | -0.74% | +407.28% | +546.58% | 44.44B | |
| -0.86% | -2.60% | +35.51% | +20.35% | 42.67B | |
| -0.14% | -2.98% | -0.04% | +82.21% | 39.96B | |
| 0.00% | -1.72% | +13.42% | +42.33% | 32.75B | |
| -3.44% | -2.43% | - | - | 17.74B | |
| -0.78% | -1.13% | +20.74% | +116.26% | 16.49B | |
| -0.37% | -2.53% | +10.91% | +30.93% | 14.38B | |
| -0.86% | -4.60% | +76.86% | +39.36% | 13.4B | |
| Average | -0.95% | -2.17% | +69.92% | +111.15% | 29.98B | |
| Weighted average by Cap. | -1.03% | -2.20% | +84.58% | +131.92% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 27.92M 0 24.03M 22.62M 20.61M 38.57M 2.66B 38.72M 268M 104M 1.35B 105M 103M 4.29B | 232M 0 199M 188M 171M 320M 22.03B 321M 2.22B 859M 11.23B 869M 851M 35.56B |
| Net income | -466M -0 -401M -378M -344M -644M -44.34B -646M -4.48B -1.73B -22.59B -1.75B -1.71B -71.57B | -322M -0 -277M -261M -238M -445M -30.63B -446M -3.09B -1.19B -15.61B -1.21B -1.18B -49.44B |
| Net Debt | -787M -0 -677M -638M -581M -1.09B -74.9B -1.09B -7.56B -2.92B -38.16B -2.96B -2.89B -121B | -501M -0 -431M -406M -370M -692M -47.7B -695M -4.81B -1.86B -24.3B -1.88B -1.84B -76.98B |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
